Skip to main content
Premium Trial:

Request an Annual Quote

Foundation, Ariad Partner on Genomic Profiles of Lung Cancer Patients

NEW YORK (GenomeWeb News) – Foundation Medicine and Ariad Pharmaceuticals today announced a deal aimed at the genomic profiling of patients enrolled in clinical trials for Ariad's investigational dual-inhibitor of ALK and EGFR for non-small cell lung cancer and other cancers.

The firms will collaborate on the generation of genomic profile information for patients enrolled in Ariad's ongoing Phase 1/2 trial for its drug AP26113, and data will be matched with clinical observations to better understand the activity and selectivity of the drug, Foundation and Ariad said.

Financial and other terms of the deal were not disclosed.

"This study is an example of how cancer complexity often defies single-marker analysis in drug development," Foundation President and CEO Michael Pellini said in a statement. "We expect that our comprehensive genomic profile will help to identify the optimal patient population for AP26113 and may potentially enable an expedited development timeline."

On Monday the Cambridge, Mass.-based firm announced a deal with AstraZeneca to identify genomic mutations in cancer-related tumor genes.

The Scan

And a Fourth?

A fourth dose of the Pfizer-BioNTech SARS-CoV-2 vaccine in an Israeli study increased antibody levels but did not prevent Omicron variant infections, according to the Financial Times.

For Better Science Software

A virtual institute funded by former Google CEO Eric Schmidt's philanthropy aims to lure software engineers to academia, Science reports.

Recommendation Explanations

The New York Times writes that the US Centers for Disease Control and Prevention is straining to both make and explain decisions based on limited information.

Genome Research Papers on De Novo Mutation Rates, Polyploid Genotyping, Oncogene Epigenomic Translocation

In Genome Research this week: de novo mutations rates in hemoglobin subunits, analysis of variant calling methods for polyploid plants, and more.